cjc1295 and ipamorelin peptide CJC 1295 7.5mg & 15mg CJC-1295 + Ipamorelin — Peptide

Primary antibodies against the target proteins were applied and incubated overnight at 4 C

4 weeks 1 x 10 mL bottle 3 vials use 9 mL 6 weeks 2 x 10 mL bottles 6 vials use 18 mL 8 weeks 3 x 10 mL bottles 8 vials use 24 mL 12 weeks 4 x 10 mL bottles 13 vials use 39 mL Round up for priming losses, dropped syringes, and damaged swabs

CJC-1295/Ipamorelin side effects are generally limited to injection site reactions, mild water retention, and transient headaches

Individuals with a history of cancer, diabetes, or cardiovascular disease should exercise caution when using Tesamorelin or CJC-1295, as both peptides can increase IGF-1 levels, which may exacerbate these conditions

Specifically, Ipamorelin was observed to elevate growth hormone concentrations up to approximately 80 milli-international units per liter (mIU/l), which is about 26.6 nanograms per milliliter (ng/ml)